Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects

AIM: Evogliptin is a newly developed oral glucose-lowering medication of the dipeptidyl peptidase 4 (DPP-4) inhibitor class for type 2 diabetes mellitus. The combination of a DPP-4 inhibitor with pioglitazone is a promising therapeutic option. The aim of the present study was to evaluate the pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Inyoung, Kim, Yun, Yoo, Hyounggyoon, Jang, In-Jin, Yu, Kyung-Sang, Lee, SeungHwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591087/
https://www.ncbi.nlm.nih.gov/pubmed/33122892
http://dx.doi.org/10.2147/DDDT.S275336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591087/
https://www.ncbi.nlm.nih.gov/pubmed/33122892
http://dx.doi.org/10.2147/DDDT.S275336

Ejemplares similares